Based at the BioArk Tech Park in Monthey and supported by the Foundation the Ark, the Valais-based startup GaDia develops rapid diagnostic solutions aimed at improving the detection of antimicrobial resistance. The company is also currently engaged in a fundraising phase to support the next stages of its development.
Recent developments highlight progress across product evolution, regulatory milestones, research collaboration and international deployment.
New developments around the KarbaDia rapid test
Over the past year, GaDia has reported several milestones related to its KarbaDia rapid test, designed for the detection of antibiotic resistance.
Nearly a year ago, the company secured a major public tender in Italy, with the delivery of more than 100,000 tests planned over six years. This contract marked a step in the international deployment of the solution and reflects its adoption in clinical settings.
More recently, GaDia introduced a new cassette format for KarbaDia (picture in the banner). This updated version aims to improve ease of use and result interpretation, while maintaining strong clinical performance. The test has also undergone evaluations in specialized antimicrobial resistance centers.
Developed and manufactured in Switzerland, KarbaDia continues to evolve both in terms of format and market reach.
Continued progress toward IVDR compliance
GaDia has renewed its EN ISO 13485:2016 certification, a key standard for quality management systems in medical device manufacturing.
This renewal supports the company’s transition toward compliance with the European In Vitro Diagnostic Regulation (IVDR), which introduces stricter requirements for diagnostic products in Europe.
The certification process involved collaboration with Quality Austria and QMD Services as notified body for IVDR.
Collaboration to develop a rapid MRSA test
Through an Innovation Cheque awarded by Innosuisse, GaDia is developing a new rapid test targeting methicillin-resistant Staphylococcus aureus (MRSA).
The project is conducted in collaboration with NARA (Swiss National Reference Center for Emerging Antibiotic Resistance) at the University of Fribourg.
The objective is to enable faster detection of MRSA and support clinical decision-making in the context of antimicrobial resistance.
Addressing a global health challenge
Antimicrobial resistance remains a major public health concern worldwide. Rapid diagnostic tools play a key role in identifying resistant pathogens and guiding appropriate treatments.
Through product development, regulatory alignment, ongoing fundraising efforts and partnerships with clinical and research institutions, GaDia contributes to ongoing efforts in this field.
Further information
More information about GaDia:
https://gadia.ch/
KarbaDia rapid test:
https://gadia.ch/products/karbadia/
